Latest news

• EMA recommends heart risk restriction for Servier's Protelos

  EMA recommends heart risk restriction for Servier's Protelos. Use of osteoporosis drug likely to be further tightened up. ... That review brought restrictions that included a prohibition on the use of Protelos' in immobilised patients or patients with a

• EMA restricts use of Servier’s Protelos and Osseor

  EMA restricts use of Servier’ s Protelos and Osseor. Osteoporosis drugs not to be used in patients with history of blood clots. ... Elderly patients were also shown to be more at risk of contracting VTE after use of Protelos and Osseor compared with

• Process for NICE guidance re-evaluation

  Servier Laboratories, the licence holder of Protelos (strontium ranelate), which instigated the review, remains satisfied with Mr Holman's judgement that NICE acted with procedural unfairness, and therefore unlawfully, by not

• High Court rules against NICE in osteoporosis case

  High Court rules against NICE in osteoporosis case. The High Court has ruled that NICE must look again at its decision not to fund the use of osteoporosis drug Protelos on ... The High Court has ruled that the National Institute for Health and Clinical

• R&D News in brief

  Protelos shines in study. Servier's osteoporosis treatment, Protelos, is effective in reducing nonvertebral and vertebral fractures over five years, according to two new studies presented at the Sixth European Congress ... One trial of 1649